Transparency
The companies in the pharmaceutical industry work closely in a variety of ways with doctors, pharmacists, other members of the health care community or patient organizations. In these working relationships, the latter share their (specialist) knowledge and their medical experience with the pharmaceutical industry in order to continuously improve the treatment of patients through this professional exchange. The independence of doctors and of the other health care providers as well as the patient organizations are a particular asset here; there must be no doubt about the independence of the contractual partners of the pharmaceutical industry.
To ensure that the interactions meet the high integrity standards that patients, governments and other stakeholders expect, the European Federation of Pharmaceutical Industries and Associations (EFPIA) and its member associations and companies have adopted codes and guidelines. The EFPIA Disclosure Code was created to foster greater transparency and build greater trust between the pharmaceutical industry, the medical community and wider society.
Our company discloses any direct or indirect transfers of value (monetary or in-kind) in compliance with the EFPIA Disclosure Code.
Allergopharma was a subsidiary of the Merck Group until March 31, 2020. Our company has been part of the Dermapharm Group since April 1st, 2020. The transparency publications of Allergopharma for January 1, 2020 to March 31, 2020 and for the previous years (from 2015) are recorded in the transparency publications of the Merck Group.
This transparency publication covers the period from April 1st, 2020 to December 31st, 2020.
Allergopharma documents and discloses all its transfers of value in all EFPIA countries in which the company is active. As of June 2019, the EFPIA countries include: Austria, Belgium, Bosnia and Herzegovina, Bulgaria, Croatia, Cyprus, Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Italy, Latvia, Lithuania, Malta, the Netherlands, North Macedonia, Norway, Poland, Portugal, Romania, Russia, Serbia, Slovakia, Slovenia, Spain, Sweden, Switzerland, Turkey, Ukraine and the United Kingdom.
In countries that are not listed below, Allergopharma has not made any transfers of value.
